Relationships between authorship contributions and authors' industry financial ties among oncology clinical trials

Journal of Clinical Oncology

Volumn 28, Issue 8, 2010, Pages 1316-1321

  Rose, Susannah L ^a   Krzyzanowska, Monika K ^a   Joffe, Steven ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL PRODUCT;

ARTICLE; AUTHORITY; CANCER RESEARCH; CLINICAL TRIAL (TOPIC); CONSULTATION; EMPLOYMENT; FINANCIAL MANAGEMENT; FUNDING; HUMAN; HYPOTHESIS; METHODOLOGY; MULTICENTER STUDY (TOPIC); PERFORMANCE MEASUREMENT SYSTEM; PRIORITY JOURNAL; PUBLICATION; BIBLIOMETRICS; CLINICAL TRIAL; CONFLICT OF INTEREST; DRUG INDUSTRY; ECONOMICS; ETHICS; INTERNATIONAL COOPERATION; INTERPERSONAL COMMUNICATION; MULTIVARIATE ANALYSIS; NEOPLASM; PRACTICE GUIDELINE; PUBLISHING; STATISTICAL MODEL; WRITING;

AUTHORSHIP; BIBLIOMETRICS; CLINICAL TRIALS AS TOPIC; CONFLICT OF INTEREST; DISCLOSURE; DRUG INDUSTRY; EDITORIAL POLICIES; FINANCIAL SUPPORT; GUIDELINE ADHERENCE; HUMANS; INTERNATIONAL COOPERATION; LIKELIHOOD FUNCTIONS; LINEAR MODELS; MULTIVARIATE ANALYSIS; NEOPLASMS; PERIODICALS AS TOPIC;

EID: 77950471768     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2008.21.6606     Document Type: Article

References (46)

1. Bodenheimer T: Uneasy alliance-clinical investigators and the pharmaceutical industry. N Engl J Med 342:1539-1544, 2000
2. DeAngelis CD: The influence of money on medical science. JAMA 296:996-998, 2006
3. Djulbegovic B, Angelotta C, Knox KE, et al: The sound and the fury: Financial conflicts of interest in oncology. J Clin Oncol 25:3567-3569, 2007 (Pubitemid 47372591)
4. Morin K, Rakatansky H, Riddick FA Jr, et al: Managing conflicts of interest in the conduct of clinical trials. JAMA 287:78-84, 2002 (Pubitemid 34251679)
5. Korn D: Conflicts of interest in biomedical research. JAMA 284:2234-2237, 2000
6. Saul S: Experts conclude Pfizer manipulated studies. The New York Times, Oct. 8, 2008, p. B4
7. Report on Individual and Institutional Financial Conflict of Interest: Task Force on Research Accountability. Washington, DC, Association of American Universities, 2001
8. Buchkowsky SS, Jewesson PJ: Industry sponsorship and authorship of clinical trials over 20 years. Ann Pharmacother 38:579-585, 2004 (Pubitemid 38352217)
9. Blumenthal D, Campbell EG, Causino N, et al: Participation of life-science faculty in research relationships with industry. N Engl J Med 335:1734-1739, 1996 (Pubitemid 26399349)
10. Boyd EA, Bero LA: Assessing faculty financial relationships with industry: A case study. JAMA 284:2209-2214, 2000
11. George B, Simhan S, Lee JA, et al: Conflicts of interest among articles published in the J Clin Oncol. J Clin Oncol 25:355s, 2007 (abstr 6633)
12. Bekelman JE, Li Y, Gross CP: Scope and impact of financial conflicts of interest in biomedical research: A systematic review. JAMA 289:454-465, 2003 (Pubitemid 36119966)
13. Gross CP, Gupta AR, Krumholz HM: Disclosure of financial competing interests in randomised controlled trials: Cross sectional review. BMJ 326: 526-527, 2003 (Pubitemid 36313213)
14. Hampson LA, Joffe S, Fowler R, et al: Frequency, type, and monetary value of financial conflicts of interest in cancer clinical research. J Clin Oncol 25:3609-3614, 2007 (Pubitemid 47372598)
15. Johnston KL, Go RS: Financial conflicts of interest among ASCO Annual Meeting abstract authors, speakers, and planners. J Natl Cancer Inst 99:1415-1416, 2007 (Pubitemid 351767181)
16. Davidson RA: Source of funding and outcome of clinical trials. J Gen Intern Med 1:155-158, 1986
17. Bhandari M, Busse JW, Jackowski D, et al: Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ 170:477-480, 2004 (Pubitemid 38293642)
18. Als-Nielsen B, Chen W, Gluud C, et al: Association of funding and conclusions in randomized drug trials: A reflection of treatment effect or adverse events? JAMA 290:921-928, 2003
19. Djulbegovic B, Lacevic M, Cantor A, et al: The uncertainty principle and industry-sponsored research. Lancet 356:635-638, 2000 (Pubitemid 30627590)
20. Heres S, Davis J, Maino K, et al: Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: An exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 163:185-194, 2006 (Pubitemid 44480836)
21. Jorgensen AW, Hilden J, Gotzsche PC: Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: Systematic review. BMJ 333:782-785, 2006 (Pubitemid 44583357)
22. Kjaergard LL, Als-Nielsen B: Association between competing interests and authors' conclusions: Epidemiological study of randomised clinical trials published in the BMJ. BMJ 325:249-252, 2002 (Pubitemid 34864391)
23. Lexchin J, Bero LA, Djulbegovic B, et al: Pharmaceutical industry sponsorship and research outcome and quality: Systematic review. BMJ 326: 1167-1170, 2003 (Pubitemid 36649048)
24. Ridker PM, Torres J: Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005. JAMA 295:2270-2274, 2006
25. Tungaraza T, Poole R: Influence of drug company authorship and sponsorship on drug trial outcomes. Br J Psychiatry 191:82-83, 2007 (Pubitemid 47035186)
26. Yank V, Rennie D, Bero LA: Financial ties and concordance between results and conclusions in meta-analyses: Retrospective cohort study. BMJ 335:1202-1205, 2007 (Pubitemid 350273305)
27. Booth CM, Cescon DW, Wang L, et al: Evolution of the randomized controlled trial in oncology over three decades. J Clin Oncol 26:5458-5464, 2008
28. Rochon PA, Gurwitz JH, Simms RW, et al: A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Arch Intern Med 154:157-163, 1994
29. Friedberg M, Saffran B, Stinson TJ, et al: Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA 282: 1453-1457, 1999 (Pubitemid 29493799)
30. Nieto A, Mazon A, Pamies R, et al: Adverse effects of inhaled corticosteroids in funded and nonfunded studies. Arch Intern Med 167:2047-2053, 2007 (Pubitemid 350036703)
31. Johansen HK, Gotzsche PC: Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA 282:1752-1759, 1999 (Pubitemid 29533606)
32. Perlis RH, Perlis CS, Wu Y, et al: Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatry 162:1957-1960, 2005
33. Stelfox HT, Chua G, O'Rourke K, et al: Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med 338:101-106, 1998 (Pubitemid 28042274)
34. Friedman LS, Richter ED: Relationship between conflicts of interest and research results. J Gen Intern Med 19:51-56, 2004 (Pubitemid 38221951)
35. Haller DG: JCO and the public trust. J Clin Oncol 24:323-324, 2006
36. Journal of Clinical Oncology: Author Disclosure Declaration (Version 091707), 2007. http://jco.ascopubs.org/misc/jco-disclosure-contribution.pdf
37. Journal of Clinical Oncology: Authorship contributions: Information for contributors, 2008. http://jco.ascopubs.org/ifc/index.dtl
38. International Committee of Medical Journal Editors: Authorship and Contributorship: Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication, 2007. http://www.icmje.org/#author
39. Donner A, Klar ND: Design and Analysis of Cluster Randomization Trials in Health Research. New York, NY, Oxford University Press, 2000
40. Riechelmann RP, Wang L, O'Carroll A, et al: Disclosure of conflicts of interest by authors of clinical trials and editorials in oncology. J Clin Oncol 25:4642-4647, 2007 (Pubitemid 350035325)
41. Ackerly N, Eyraud J, Mazzotta M: Measuring conflicts of interest and expertise on FDA advisory committees. Office of Policy, Planning and Preparedness, U.S. Food and Drug Administration, 2007 http://www.fda.gov/oc/ advisory/ergcoireport.pdf
42. American Society of Clinical Oncology: Revised conflict of interest policy. J Clin Oncol 24:519-521, 2006
43. Ross JS, Hill KP, Egilman DS, et al: Guest authorship and ghostwriting in publications related to rofecoxib: A case study of industry documents from rofecoxib litigation. JAMA 299:1800-1812, 2008
44. Hwang SS, Song HH, Baik JH, et al: Researcher contributions and fulfillment of ICMJE authorship criteria: Analysis of author contribution lists in research articles with multiple authors published in radiology. Radiology 226:16-23, 2003 (Pubitemid 36163902)
45. Bates T, Anic A, Marusic M, et al: Authorship criteria and disclosure of contributions: Comparison of 3 general medical journals with different author contribution forms. JAMA 292:86-88, 2004
46. Baerlocher MO, Newton M, Gautam T, et al: The meaning of author order in medical research. J Investig Med 55:174-180, 2007 (Pubitemid 47492776)